Network‐based drugs and biomarkers

The structure and dynamics of protein signalling networks governs cell decision processes and the formation of tissue boundaries. Complex diseases such as cancer and diabetes are diseases of such networks. Therefore approaches that can give insight into how these networks change during disease progression are crucial for better understanding, detection and intervention. The era of network medicine has begun; however, there are fundamental principles associated with molecular networks that are essential to consider for this field to succeed. Here, we introduce network biology and some of its associated technologies. We then focus on the multivariate nature of cellular networks and how this has implications for biomarker and drug discovery using cancer metastasis as an example. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[2]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[3]  M. Saraste,et al.  FEBS Lett , 2000 .

[4]  R. Khokha,et al.  Molecular mechanisms of tumor invasion and metastasis: an integrated view. , 2003, Current molecular medicine.

[5]  J. Segall,et al.  Intravital imaging of cell movement in tumours , 2003, Nature Reviews Cancer.

[6]  J. Shendure,et al.  Advanced sequencing technologies: methods and goals , 2004, Nature Reviews Genetics.

[7]  M. Mann,et al.  Mass spectrometry–based proteomics turns quantitative , 2005, Nature chemical biology.

[8]  D. Lauffenburger,et al.  A Systems Model of Signaling Identifies a Molecular Basis Set for Cytokine-Induced Apoptosis , 2005, Science.

[9]  Michael B. Yaffe,et al.  Data-driven modelling of signal-transduction networks , 2006, Nature Reviews Molecular Cell Biology.

[10]  T. Pawson,et al.  Reading protein modifications with interaction domains , 2006, Nature Reviews Molecular Cell Biology.

[11]  P. Steeg.  Tumor metastasis: mechanistic insights and clinical challenges , 2006, Nature Medicine.

[12]  D. Lauffenburger,et al.  Applying computational modeling to drug discovery and development. , 2006, Drug discovery today.

[13]  Quynh-Thu Le,et al.  Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.

[14]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[15]  Charles Auffray,et al.  Protein subnetwork markers improve prediction of cancer outcome , 2007, Molecular systems biology.

[16]  C. Bakal,et al.  Quantitative Morphological Signatures Define Local Signaling Networks Regulating Cell Morphology , 2007, Science.

[17]  A. Barabasi,et al.  Network medicine--from obesity to the "diseasome". , 2007, The New England journal of medicine.

[18]  P. Bork,et al.  Systematic Discovery of In Vivo Phosphorylation Networks , 2007, Cell.

[19]  Forest M White,et al.  Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma , 2007, Proceedings of the National Academy of Sciences.

[20]  Genee Y. Lee,et al.  The morphologies of breast cancer cell lines in three‐dimensional assays correlate with their profiles of gene expression , 2007, Molecular oncology.

[21]  Douglas A. Lauffenburger,et al.  Common effector processing mediates cell-specific responses to stimuli , 2007, Nature.

[22]  T. Ideker,et al.  Network-based classification of breast cancer metastasis , 2007, Molecular systems biology.

[23]  D. Lauffenburger,et al.  Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks , 2007, Proceedings of the National Academy of Sciences.

[24]  Erik Sahai,et al.  Illuminating the metastatic process , 2007, Nature Reviews Cancer.

[25]  C. Bakal,et al.  Phosphorylation Networks Regulating JNK Activity in Diverse Genetic Backgrounds , 2008, Science.

[26]  T. Pawson,et al.  Network medicine , 2008, FEBS letters.

[27]  P. Bork,et al.  Linear Motif Atlas for Phosphorylation-Dependent Signaling , 2008, Science Signaling.

[28]  Rune Linding,et al.  Directional and quantitative phosphorylation networks. , 2008, Briefings in functional genomics & proteomics.

[29]  R. Hill,et al.  The tumor microenvironment and metastatic disease , 2008, Clinical & Experimental Metastasis.

[30]  R. Sharan,et al.  Protein networks in disease. , 2008, Genome research.

[31]  A. Henney,et al.  A network solution , 2008, Nature.

[32]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[33]  Valerie M. Weaver,et al.  Three-dimensional context regulation of metastasis , 2008, Clinical & Experimental Metastasis.

[34]  Dynamic imaging of cancer invasion and metastasis: principles and preclinical applications , 2009, Clinical & Experimental Metastasis.

[35]  J. Erler,et al.  Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. , 2009, Cancer cell.

[36]  Tony Pawson,et al.  Comparative Analysis Reveals Conserved Protein Phosphorylation Networks Implicated in Multiple Diseases , 2009, Science Signaling.

[37]  Tony Pawson,et al.  Positive Selection of Tyrosine Loss in Metazoan Evolution , 2009, Science.

[38]  V. Grantcharova,et al.  Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.

[39]  E. Golemis,et al.  Targeting EGFR resistance networks in head and neck cancer. , 2009, Cellular signalling.

[40]  D. Lauffenburger,et al.  Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death , 2009, Molecular Cancer Therapeutics.

[41]  G. Superti-Furga,et al.  Charting the molecular network of the drug target Bcr-Abl , 2009, Proceedings of the National Academy of Sciences.

[42]  J. Reis-Filho,et al.  The role of molecular analysis in breast cancer , 2009, Pathology.

[43]  Emmanuel D. Levy,et al.  How Perfect Can Protein Interactomes Be? , 2009, Science Signaling.

[44]  Joe W. Gray,et al.  HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment , 2010, Breast Cancer Research and Treatment.

[45]  J. Uhm.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .

[46]  E. Golemis,et al.  Mechanisms of tumor resistance to EGFR-targeted therapies , 2009, Expert opinion on therapeutic targets.

[47]  David Warde-Farley,et al.  Dynamic modularity in protein interaction networks predicts breast cancer outcome , 2009, Nature Biotechnology.

[48]  Mechanisms of tumor resistance to EGFR-targeted therapies. , 2009, Expert opinion on therapeutic targets.

[49]  P. Sorger,et al.  Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.

[50]  Julio Saez-Rodriguez,et al.  Fuzzy Logic Analysis of Kinase Pathway Crosstalk in TNF/EGF/Insulin-Induced Signaling , 2007, PLoS Comput. Biol..